TRANSGENE

NOVEL ANTIBODIES AND NUCLEOTIDE SEQUENCES, AND USES THEREOF

N° US2025257135A1

RECOMBINANT VIRUS EXPRESSING INTERLEUKIN-12

N° MX2024015241A

M2-DEFECTIVE POXVIRUS

N° JP2024174985A

NOVEL ANTIBODIES AND NUCLEOTIDE SEQUENCES, AND USES THEREOF

N° JP2024091656A

Novel combinations of antibodies and uses thereof

N° IL311234A

PARAPOXVIRUS VECTORS

N° JP2024050588A

The polarity and specificity of sars-cov2 -specific t lymphocyte responses as a biomarker of disease susceptibility

N° IL308102A

RECOMBINANT PSEUDOCOWPOX VIRUS ENCODING AN INTERLEUKIN-12

N° WO2024062098A1

CHIMERIC POXVIRUSES

N° EP4573113A1

CHIMERIC POXVIRUSES

N° AU2023326730A1

CHIMERIC POXVIRUSES

N° WO2024038175A1

키메라 폭스바이러스

N° KR20250052416A

Chimeric poxviruses

N° TW202413636A

FUSION PROTEIN COMPRISING A SURFACTANT-PROTEIN-D AND A MEMBER OF THE TNFSF

N° WO2024003353A1

계면활성제-단백질-D 및 TNFSF의 구성원을 포함하는 융합 단백질

N° KR20250034101A

FUSION PROTEIN COMPRISING A SURFACTANT-PROTEIN-D AND A MEMBER OF THE TNFSF

N° AU2023300419A1

Fusion proteins comprising surfactant protein-d and TNFSF members

N° CN119654339A

FUSION PROTEIN COMPRISING A SURFACTANT-PROTEIN-D AND A MEMBER OF THE TNFSF

N° EP4547705A1

PERSONALIZED VACCINE

N° JP2023123609A

RECOMBINANT VIRUS EXPRESSING INTERLEUKIN-12

N° WO2023238106A1

RECOMBINANT VIRUS EXPRESSING INTERLEUKIN-12

N° EP4536838A1

RECOMBINANT VIRUS EXPRESSING INTERLEUKIN-12

N° AU2023283081A1

인터루킨-12를 발현하는 재조합 바이러스

N° KR20250022783A

Recombinant virus expressing interleukin-12

N° CN119677861A

FUSION POLYPEPTIDE COMPRISING AN ANTI-PD-L1 SDAB AND A MEMBER OF THE TNFSF

N° WO2023213764A1

POXVIRUS ENCODING A BINDING AGENT COMPRISING AN ANTI- PD-L1 SDAB

N° WO2023213763A1

PERSONALIZED VACCINE

N° US2023277639A1

IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY

N° US2024024437A1

NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF

N° WO2023046777A1

NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF

N° US2024374719A1

항체의 신규 조합 및 이의 용도

N° KR20240067076A

NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF

N° EP4405050A1

NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF

N° AU2022351060A1

NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF

N° CA3231396A1

Novel combinations of antibodies and uses thereof

N° TW202321458A

DELIVERY SYSTEM FOR TARGETING GENES OF THE INTERFERON PATHWAY

N° WO2023025899A2

Process for designing a recombinant poxvirus for a therapeutic vaccine

N° IL294057A

THE POLARITY AND SPECIFICITY OF SARS-COV2 -SPECIFIC T LYMPHOCYTE RESPONSES AS A BIOMARKER OF DISEASE SUSCEPTIBILITY

N° EP4330674A1

THE POLARITY AND SPECIFICITY OF SARS-COV2 -SPECIFIC T LYMPHOCYTE RESPONSES AS A BIOMARKER OF DISEASE SUSCEPTIBILITY

N° AU2022266083A1

THE POLARITY AND SPECIFICITY OF SARS-COV2 -SPECIFIC T LYMPHOCYTE RESPONSES AS A BIOMARKER OF DISEASE SUSCEPTIBILITY

N° WO2022229461A1

THE POLARITY AND SPECIFICITY OF SARS-COV2 -SPECIFIC T LYMPHOCYTE RESPONSES AS A BIOMARKER OF DISEASE SUSCEPTIBILITY

N° CA3217132A1

Polaridade e especificidade de respostas de linfócitos t específicos para sars-cov-2 como um biomarcador de suscetibilidade à doença

N° BR112023022655A2

THE POLARITY AND SPECIFICITY OF SARS-COV2 -SPECIFIC T LYMPHOCYTE RESPONSES AS A BIOMARKER OF DISEASE SUSCEPTIBILITY.

N° MX2023012874A

Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody

N° IL291427A

VECTORIZATION OF MUC1 T CELL ENGAGER

N° WO2022148736A1

TREATMENT OF IMMUNE DEPRESSION

N° CA3189238A1

TREATMENT OF IMMUNE DEPRESSION

N° US2023256057A1

TREATMENT OF IMMUNE DEPRESSION

N° WO2022013221A1

TREATMENT OF IMMUNE DEPRESSION

N° EP4178605A1

Treatment of immune depression

N° AU2021309007A1

면역 억제의 치료

N° KR20230038496A

Treatment of immune depression

N° TW202217002A

Immunosuppressive treatments

N° CN116322740A

M2-defective poxvirus

N° IL284421A

Novel antibodies and nucleotide sequences, and uses thereof

N° IL281198A

PROCESS FOR DESIGNING A RECOMBINANT POXVIRUS FOR A THERAPEUTIC VACCINE

N° WO2021130210A1

PROCESS FOR DESIGNING A RECOMBINANT POXVIRUS FOR A THERAPEUTIC VACCINE

N° EP4081245A1

Process for designing a recombinant poxvirus for a therapeutic vaccine

N° AU2020415310A1

PROCESS FOR DESIGNING A RECOMBINANT POXVIRUS FOR A THERAPEUTIC VACCINE

N° CA3164794A1

치료용 백신을 위한 재조합 폭스바이러스를 설계하는 방법

N° KR20220119637A

Method for designing recombinant poxvirus for therapeutic vaccines

N° CN115916246A

PROCESS FOR DESIGNING A RECOMBINANT POXVIRUS FOR A THERAPEUTIC VACCINE

N° US2023081457A1

ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS

N° JP2021006048A

HPV 폴리펩티드 및 IL-2를 암호화하는 폭스바이러스와 항-PD-L1 항체의 조합

N° KR20220068242A

COMBINATION OF A POXVIRUS ENCODING HPV POLYPEPTIDES AND IL-2 WITH AN ANTI-PD-L1 ANTIBODY

N° WO2021053207A1

COMBINATION OF A POXVIRUS ENCODING HPV POLYPEPTIDES WITH AN ANTI-PD-L1 ANTIBODY

N° US2023405105A1

COMBINATION OF A POXVIRUS ENCODING HPV POLYPEPTIDES AND IL-2 WITH AN ANTI-PD-L1 ANTIBODY

N° EP4031573A1

COMBINATION OF A POXVIRUS ENCODING HPV POLYPEPTIDES AND IL-2 WITH AN ANTI-PD-L1 ANTIBODY

N° CA3155090A1

COMBINATION OF A POXVIRUS ENCODING HPV POLYPEPTIDES AND IL-2 WITH AN ANTI-PD-L1 ANTIBODY.

N° MX2022002883A

Combination of a poxvirus encoding HPV polypeptides and IL-2 with an anti-PD-L1 antibody

N° AU2020350137A1

Parapoxvirus vectors

N° IL277161A

COMBINATION OF ONCOLYTIC VIRUS WITH IMMUNE CHECKPOINT MODULATORS

N° US2020376052A1

COMBINATION OF ONCOLYTIC VIRUS WITH IMMUNE CHECKPOINT MODULATORS

N° JP2020183392A

Oncolytic virus for expression of immune checkpoint modulators

N° AU2020200541A1

M2-DEFECTIVE POXVIRUS.

N° MX2021007860A

POXVÍRUS MODIFICADO, MÉTODO PARA PRODUZIR O POXVÍRUS MODIFICADO, COMPOSIÇÃO E USOS DA COMPOSIÇÃO

N° BR112021012630A2

M2-DEFECTIVE POXVIRUS

N° CN113453712A

M2-defective poxvirus

N° AU2019412516A1

M2-DEFECTIVE POXVIRUS

N° EP3902562A1

M2-DEFECTIVE POXVIRUS

N° US2022056481A1

M2 결함성 폭스바이러스

N° KR20210110838A

IMMUNOSUPPRESSIVE M2 PROTEIN

N° WO2020136232A1

M2-DEFECTIVE POXVIRUS

N° WO2020136235A1

M2-DEFECTIVE POXVIRUS

N° CA3124773A1

M2-DEFECTIVE POXVIRUS

N° SG11202106898VA

PROCESS FOR DESIGNING A RECOMBINANT POXVIRUS FOR A THERAPEUTIC VACCINE

N° EP3842065A1

Oncolytic virus for expression of immune checkpoint modulators

N° US2020197457A1

Personalized vaccine

N° IL271558A

PRODUCTION OF VIRAL VACCINES ON AN AVIAN CELL LINE

N° CA3123105A1

PRODUCTION OF VIRAL VACCINES ON AN AVIAN CELL LINE

N° WO2020120910A1

Produção de vacinas virais em uma linha celular aviária

N° BR112021011362A2

PRODUCTION OF VIRAL VACCINES ON AN AVIAN CELL LINE

N° EP3893928A1

PRODUCTION OF VIRAL VACCINES ON AN AVIAN CELL LINE

N° CN113490507A

PRODUCTION OF VIRAL VACCINES ON AN AVIAN CELL LINE

N° US2022054618A1

Novel antibodies and nucleotide sequences and uses thereof

N° CN119161482A

NOVEL ANTIBODIES AND NUCLEOTIDE SEQUENCES, AND USES THEREOF

N° WO2020049001A1

molécula de anticorpo, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, e, método para tratar câncer em um sujeito

N° BR112021003916A2

NOVEL ANTIBODIES AND NUCLEOTIDE SEQUENCES, AND USES THEREOF

N° EP3847193A1

신규 항체 및 뉴클레오티드 서열 및 이의 용도

N° KR20210055722A

Novel antibodies and nucleotide sequences, and uses thereof

N° AU2019333862A1